Clinical Trial Update: Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation [Phase 3]

View source ↗

Summary

Phase 3 study of adagrasib (MRTX849) versus docetaxel in advanced/metastatic KRAS G12C non-small cell lung cancer is active/not recruiting with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Adagrasib (adagrasib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Mirati Therapeutics Inc. | Conditions: Metastatic Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-01-22